Outcome of the Board Meeting dated May 16, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.8 pts more than Nifty Microcap 250 and 5.0 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025, with an unmodified audit opinion from Sarda Soni Associates LLP. Standalone revenue from operations surged ~66% YoY to ₹2,199.90 lakhs (vs ₹1,320.49 lakhs in FY24), while the company swung from a loss of ₹267.22 lakhs in FY24 to a profit of ₹207.26 lakhs in FY25, with EPS improving to ₹2.01 from negative ₹2.60. Operating cash flow was healthy at ₹187.70 lakhs and cash balance rose to ₹175.24 lakhs. The Board also appointed Nilesh A. Pradhan & Co. LLP as Secretarial Auditor for 5 years (FY26–FY30), Vishal J Bhanushali & Associates as Internal Auditor for FY26, and approved re-appointment of Dr. Pankaj Shah as MD & CEO for 3 years (Aug 2025–Jul 2028), subject to shareholder approval via postal ballot.
This is a significant turnaround year for Aspira Pathlab, with strong revenue growth, return to profitability, and clean audit opinion — likely to be viewed positively by investors. The MD re-appointment provides leadership continuity, while the postal ballot (record date June 6, 2025) gives shareholders a direct say on his remuneration.